{"Clinical Trial ID": "NCT00213980", "Intervention": ["INTERVENTION 1:", "zoledronic acid (ZA)", "- ZA", "zoledronic acid (ZA): 4 mg IV in 15 minutes once every 12 weeks for 4 cycles", "INTERVENTION 2:", "Comment", "Observation only for 12 months"], "Eligibility": ["Incorporation criteria:", "Menopausal women, stage III or positive axillary ganglion", "Currently, the disease is free from breast cancer and other invasive malignancies at the time of registration.", "No concomitant use of bisphosphonates", "- Exclusion criteria:", "Metastatic diseases"], "Results": ["Performance measures:", "Change in bone mineral density (BMD) from 1 year reference value", "To determine if zoledronate 4 mg IV every 12 weeks x 4 doses is associated with an increase in bone mineral density in the lumbar spine and femoral head, calculated from initial data and one-year data.", "Time limit: up to 1 year", "Results 1:", "Title of arm/group: Zoledronic acid (ZA)", "Description of the arm/group: ZA", "zoledronic acid (ZA): 4 mg IV in 15 minutes once every 12 weeks for 4 cycles", "Total number of participants analysed: 29", "Average (95% confidence interval)", "Unit of measurement: grams per cubic centimeter Lumbar spin L1-L4 (L1-L4): 0.048 (0.034 to 0.062)", "- Femoral neckline (FN): 0.014 (0.002 to 0.027)", "Total femur (TF): 0.019 (0.011 to 0.026)", "Trochantier (T): 0.023 (0.013 to 0.34)", "- Calcan (OC): 0.010 (0.004 to 0.015)", "Results 2:", "Title of the arm/group: Observation", "Description of the arm/group: Observation only for 12 months", "Total number of participants analysed: 27", "Average (95% confidence interval)", "Unit of measurement: grams per cubic centimeter Lumbar spin L1-L4 (L1-L4): 0.007 (-0.020 to 0.034)", "- Femoral neckline (FN): 0.005 (-0.012 to 0.023)", "Total femur (TF): 0.004 (-0.006 to 0.015)", "- Trochantier (T): 0.005 (-0.007 to 0.017)", "- Calcan (OC): 0.001 (-0.007 to 0.005)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/32 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}